VIVA BIOTECH repurchased VIVA Shanghai's obligations, temporarily suspended by investors
VIVA BIOTECH (01873.HK) announced that the company received a letter from VIVA Shanghai investors (including HLC SPV, Qingdao Hongyi, Daxue Investments, True Light P, and Raed Capital Holdings 2), irrevocably agreeing to temporarily suspend their right to require the company to repurchase their equity in VIVA Shanghai under the repurchase obligation at any time from December 31, 2026, to December 31, 2028.
According to the shareholder agreement, VIVA Shanghai investors have the right to repurchase their equity if VIVA Shanghai fails to complete a qualified initial public offering or achieve a qualified merger and acquisition transaction by December 31, 2026
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments